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Abstract
Background To eliminate some of the potential late limita-
tions of permanent metallic stents, the bioresorbable coro-
nary stents or ‘bioresorbable vascular scaffolds’ (BVS) have
been developed.
Methods We reviewed all currently available clinical data
on BVS implantation.
Results Since the 2015 position statement on the appro-
priateness of BVS in percutaneous coronary interventions,
several large randomised trials have been presented. These
have demonstrated that achieving adequate 1 and 2 year
outcomes with these first-generation BVS is not straight-
forward. These first adequately powered studies in non-
complex lesions showed worse results if standard implan-
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tation techniques were used for these relatively thick scaf-
folds. Post-hoc analyses hypothesise that outcomes similar
to current drug-eluting stents are still possible if aggres-
sive lesion preparation, adequate sizing and high-pressure
postdilatation are implemented rigorously. As long as this
has not been confirmed in prospective studies the usage
should be restricted to experienced centres with continuous
outcome monitoring. For more complex lesions, results are
even more disappointing and usage should be discouraged.
When developed, newer generation scaffolds with thinner
struts or faster resorption rates are expected to improve out-
comes. In the meantime prolonged dual antiplatelet therapy
(DAPT, beyond one year) is recommended in an individu-
alised approach for patients treated with current generation
BVS.
Conclusion The new 2017 recommendations downgrade
and limit the use of the current BVS to experienced centres
within dedicated registries using the updated implantation
protocol and advise the prolonged usage of DAPT. In line
with these recommendations the manufacturer does not sup-
ply devices to the hospitals without such registries in place.
Keywords Bioresorbable vascular scaffold · Percutaneous
coronary intervention · Absorb BVS
Introduction
Drug-eluting stents (DES) are widely used and considered
first choice devices in percutaneous coronary interventions
(PCI) to treat ischaemic coronary artery disease [1]. These
permanent implants, however, do not have any residual
function after vascular healing following PCI. Beyond the
initial healing period, metallic stents may induce new prob-
lems, resulting in an average reintervention rate of 2% per
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year [2]. To eliminate some of the potential late limitations
of permanent metallic DES, such as impaired vasomotion,
hampered endothelial function, reduced potential for ves-
sel remodelling and interference with future non-invasive
imaging (cardiac computed tomography or magnetic res-
onance imaging) or treatment modalities (re-PCI or coro-
nary artery bypass grafting), bioresorbable coronary stents
or ‘bioresorbable vascular scaffolds’ (BVS) have been de-
veloped. As clinical evidence is accumulating, we have up-
dated the 2015 Dutch recommendations on the use of BVS
in PCI [3].
Lesion selection
The short-term efficacy of BVS in patients with non-com-
plex coronary lesions has been investigated and reported
in four large independent randomised trials (ABSORB II,
ABSORB China, ABSORB Japan and ABSORB III [4–7]).
The characteristics of these ‘Absorb 2/3-like lesions’ are
summarised in Table 1.
At 1 year, Absorb BVS (Abbott Vascular, Santa Clara,
CA) were demonstrated to be non-inferior to Abbott’s
Xience DES regarding the combined and individual clin-
ical endpoints of death, myocardial infarction (MI), and
target lesion failure/revascularisation. These results were
confirmed in a meta-analysis of randomised clinical trial
data at 1 year, comprising 3389 patients randomised in
a 2:1 fashion to Absorb BVS and Xience DES, respectively
[8]. However, a signal of higher incidence of target vessel
MI was reported, partly due to a non-significant nominal
increase in device thrombosis (hazard ration (HR) 2.09). In
the longer term, the 5-year results of the ABSORB cohort B
trial were encouraging, showing late lumen stability and
the restoration of vasomotor function, together with low
restenosis and major adverse cardiac event (MACE) rates in
relatively simple stenotic lesions [9]. This was in line with
expectations regarding a potential long-term physiological
Table 1 BVS Absorb 2/3-like lesions
Absorb 2/3-like lesions Exclusion
De novo lesions Left main
Diameter 2.3–3.8 mm Arterial or venous grafts
Maximum length 28 mm In-stent restenosis
One BVS scaffold overlap Chronic total occlusion
Maximum 2 lesions Ostial lesions
Stable, unstable or silent
ischaemia







benefit after full bioresorption of scaffolds over permanent
metallic DES. However, after 3 years, the ABSORB II
study did not report any superiority in vasomotor reactiv-
ity of BVS over DES [10]. Moreover, the device-oriented
composite endpoint was significantly worse in the Absorb
BVS subgroup (HR 2.17), mainly due an increase in target
vessel MI (6% vs. 1%; p = 0.011).
Furthermore, also the 2 year results from the
ABSORB III study were reported [11] and the rates of
target lesion failure were significantly higher with BVS
than DES (11.0% vs. 7.9%, p = 0.03), mainly driven by an
increase in target vessel MI, which was partly due to an
increase in the incidence of scaffold thrombosis (ScT).
In the initial ABSORB trials, the implantation tech-
nique was reported to be suboptimal according to cur-
rent BVS implantation standards. In a pooled analysis
(ABSORB II, ABSORB China, ABSORB Japan and
ABSORB III and ABSORB Extend) optimal sizing, opti-
mal sizing/predilatation and optimal sizing/pre- and post-
dilatation was only achieved in about 81.6%, 59.2% and
12.4% of patients, respectively [12]. In particular optimal
sizing avoiding implantation in vessels with a reference
vessel diameter (RVD) by quantitative coronary analysis
(QCA) of <2.25 mm or >3.5 mm reduced both 2 year target
lesion failure (12.1% vs. 7.6%, p = 0.0006) and stent throm-
bosis (2.6% vs. 1.5%, p = ns) [13]. In a blinded, pooled
interim analysis of ABSORB IV, the rate of ScT at 30 days
and after 1 year was lower compared with ABSORB III
(0.3% vs. 1.0% and 0.5% vs. 1.3%, respectively), which
was attributed to higher adherence to improved implan-
tation techniques, in particular avoidance of implantation
in vessels with an RVD <2.25 (4% vs. 19%, respectively)
and applying proper post-dilatation (83% vs. 66%, respec-
tively). Still we will have to wait for the completion of this
trial to see the unblinded data.
Given the lack of clear benefit on mid-term outcomes
compared with contemporary DES with repeated signals
of safety issues regarding early, late and possibly very late
stent thrombosis, we have to downgrade the level of recom-
mendation for ‘Absorb 2/3-like lesions’ from ‘appropriate’
to ‘potentially appropriate’ and restricted to experienced
centres with continuous safety monitoring within dedicated
registries using the most recent implantation technique (as
described in the instructions for use of the device). Patient
should be well informed on the potential risks of the therapy
and the only hypothetical long-term benefit.
For patients with more complex lesions, who were ex-
cluded from the aforementioned Absorb 2/3 studies, the
mid-term outcome data of some medium-sized studies on
more complex, real-world lesions and indications have been
reported. For instance, the BVS Expand Registry, a sin-
gle-centre registry including a more complex patient and
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and a MACE rate of 6.8% at 18 months [14]. Secondly,
from a large real-world BVS registry (GHOST-EU) the
1-year clinical result data were compared with propensity-
matched patients from a large post-marketing DES reg-
istry (Xience V USA). No differences in target lesion fail-
ure, target vessel MI or stent/scaffold thrombosis were no-
ticed [15].
Recently, the Amsterdam Investigator-initiateD Absorb
Strategy all-comers trial (AIDA) trial, an investigator-initi-
ated, randomised non-inferiority trial in the context of rou-
tine clinical practice, was published early because of safety
concerns raised by the study data and safety monitoring
board (median duration of follow-up of 707 days) [16]. This
study included much more complex patients compared with
the company initiated Absorb phase 3 studies requirements
for approval. In AIDA, 54% of the patients presented with
acute coronary syndrome (ACS), which was not allowed
in the Absorb studies. A large number of complex lesions
were included (5% bifurcations, 4% chronic total occlu-
sions (CTO), 5.6% ostial and 30% moderately or severely
calcified) with on average longer lesions and more scaffolds
per patient and per lesion. Still there was no significant
difference regarding the primary endpoint of target vessel
failure at 2 years (11.7% vs. 10.7%) nor in the secondary
endpoints of target vessel and target lesion revascularisa-
tion (8.7% vs. 7.5%, 7.0% vs. 5.2%, respectively). Most
importantly, there was a highly significant difference in the
rates of definite and probable ScT at 2 years (3.5% with
BVS vs. 0.9% with metallic DES, p < 0.001). This was re-
flected in a higher rate of target vessel MI (5.5% vs. 3.2%,
p = 0.04). A more detailed analysis showed, besides an in-
crease in early and late ScT, also the occurrence of very
late ScT. For this reason, the data and safety monitoring
board recommended early reporting of the study to inform
the patients and physicians. Concerning the implantation
technique, the use of postdilatation was higher compared
with previous studies (74%) but not yet at the current target
level and as in many other studies, small vessels (refer-
ence vessel diameter 2.25 mm by QCA) accounted for
almost 20% of the lesions. Vessel size of 2.25 mm, ade-
quate device sizing or postdilatation did not seem to be not
associated with the occurrence of ScT; however, the rela-
tively small sample size (31 ScT cases) might have limited
this analysis. This contrasts with the findings from a case-
control analysis of 105 ScTs occurring in randomised con-
trolled trials (RCTs) and large registries (>200 BVS-treated
patients) with at least 12 months of follow-up [17], in which
early dual antiplatelet therapy (DAPT) cessation, no-post-
dilatation and RVD <2.4 mm were identified as predictors
for ScT.
The GHOST-EU registry included 302 bifurcation le-
sions. The rate of target lesion failure with BVS was ac-
ceptable (6.4% at 360 days). However, the rates of ScT were
elevated (2.5%) [18]. For long coronary lesions (≥60 mm),
target lesion failure rate with BVS was substantially higher
(14.3% compared with 4.8% and 4.5% for lesions <30 mm
or between 30 and 60 mm, respectively), mainly because
of an increase in MI (including ScT (3.8%)) and clinically
driven target lesion revascularisation [19]. Of note, scaf-
fold overlapping did not appear to have a negative impact
on a composite endpoint of all-cause death, any MI and
any repeated revascularisation as well as on the rate of
early or late ScT [20]. Concerning BVS implantation in
ACS patients (ST-segment elevation myocardial infarction
(STEMI), non-STEMI, unstable angina) the rates of patient-
and device-oriented endpoints, as well as ScT, were signifi-
cantly elevated compared with non-ACS patients [21]. One
multicentre, single-blinded, RCT reported on BVS use in
primary PCI in patients with STEMI. In the TROFI II study,
arterial healing with BVS implantation was comparable to
DES and nearly complete at 6 months and target lesion
revascularisation at 6 months was low in both study arms
(1.1% vs. 0%) [22]. Regarding CTOs, a recent study on
complex CTO (all lesions with J-CTO score >2, mean 2.61)
reported procedural success rates of 97.1% and favourable
mid-term results at up to 6 months with 3 MACE in 105
patients (2.9%) [23]. We have now included this group of
lesions in the general more complex group. Still, longer
follow-up is needed to draw more definitive conclusions on
BVS use in both STEMI and CTO lesions.
In summary, the new data on BVS use in more com-
plex lesions for up to 2 years is more concerning compared
with our previous analysis and we changed the previous ad-
vice from probably appropriate to discouraged for routine
clinical practice.
The data on ‘highly’ complex lesions, such as two scaf-
fold bifurcations, severely calcified lesions and aorta-ostial
lesions, however, are still premature or not in favour of BVS
use. As such, for these highly complex lesions the use of
BVS is currently not supported by expert opinion.
Furthermore, for two subsets of lesions, namely arterial
or venous grafts and in-stent restenosis, the current Absorb
BVS label (de novo lesions in native vessels) does not apply
and the off-label use of BVS should be extraordinary.
A final – technical – limitation is the overexpansion ca-
pabilities of the Absorb BVS that is currently restricted
to 0.5 mm based on the recommendation of the manufac-
turer. As the largest commercially available Absorb BVS is
3.5 mm at nominal pressure, vessels with a diameter above
4.0 mm should not be targeted because of the risk of ex-
tensive malapposition. We do not support the implantation
of BVS in lesions with an RVD below 2.25 mm (as mea-
sured by QCA) as the outcome in this lesion subgroup is
significantly worse as reported by the Absorb III trial in-
vestigators (target lesion failure: 12.9% (Absorb BVS) vs.
8.3% (Xience DES)) [5]. Another caveat is ostial coronary
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Table 2 Lesion selection Potentially appropriatea using
optimal implantation technique
(PSP)
Absorb 2/3-like lesions: ‘de novo’ lesions, max. length 28 mm, one
stent overlap, max. 2 lesions, RVD >2.25 mm on QCA
Discouraged for routine clinical
practicea
ACS patients, including STEMI
Long lesions (>28 mm, <60mm )
Moderately to severely calcified lesions with proper lesion preparation
(diameter stenosis <40% after pre-dilatation)
Provisional bifurcation treatment (including fenestration of the side
branch)
Non-complex CTO (J-CTO score <2)
Complex CTO (J-CTO score ≥2)
Use not supported by data or
expert opinion
Very long lesions (≥60 mm)
Ostial coronary lesions
Severely calcified lesions with failure to prepare properly
Bifurcation lesions requiring a two scaffold approach
Not recommended RVD <2.5 (2.25 mm on QCA)
In-stent restenosisb
Arterial and venous graftsb
Vessel >4.0 mm in diameterb
ACS acute coronary syndrome, CTO chronic total occlusion, PSP pre-dilate, size properly and post-dilate,
QCA quantitative coronary analysis, RVD reference vessel diameter, STEMI ST-elevation myocardial infarc-
tion
aUse restricted to dedicated BVS clinical trial/registries
bOff-label use
Table 3 Patient selection
Optimal Patient with good life expectancy (i. e. >5 years) Age <70 years or Age 70–80 with a maximum of 1 of:
severe renal failure or dialysis, DM, BMI >40 or LVEF
<40%, stroke, PAD or COPD
No potential benefit to be
expected
Patient with limited life expectancy (i. e.
<2–3 years)
Cardiogenic shock, severe heart failure (EF <30%), dialy-
sis
Avoid No use in emergency bail-out situations
Patients on oral anticoagulants
–
BMI body mass index, COPD obstructive pulmonary disease, DM diabetes mellitus, LVEF left ventricular ejection fraction, PAD peripheral artery
disease
lesions, as was suggested by data from the GHOST-EU
registry [24]. The composite endpoint of a combination of
cardiovascular death, target vessel MI or target lesion revas-
cularisation was significantly higher in ostial lesions (12.6%
vs. 4.6%) as was the incidence of ScT (4.9% vs. 2.0%). The
use of BVS in this group is not supported by sufficient data,
and the authors of this consensus statement advise to avoid
use in these lesions until more data are available.
Table 2 provides the advice of the authors on lesion char-
acteristics used for identification of possible target lesions
as descripted above.
Patient selection
As bioresorbable scaffolds resolve 2–3 years after implanta-
tion, improvement in patient outcomes in comparison with
permanent metallic structures, if present, will probably be
most evident in patients whose life expectancy exceeds
those first years of implantation.
It is therefore essential to appropriately select patients
in which BVS may yield the highest advantage on long-
time clinical outcome compared with DES. The ideal BVS
candidate is a young first time presenter with a good life
expectancy (>5 years). On the other hand, patients above
80 years, patients with severe renal failure or on dialysis
and patients who are in cardiogenic shock at the time of the
implantation only have a limited life expectancy [25] and
therefore the potential for a long-term benefit of BVS com-
pared with DES is severely hampered. Other patient-related
conditions, such as diabetes mellitus, body mass index >40,
left ventricular ejection fraction <40%, previous stroke, pe-
ripheral artery disease and chronic obstructive pulmonary
disease, also have a negative impact on patient’s life ex-
pectancy and should be carefully weighted in terms of risks
and benefits. In Table 3 we summarise the patient charac-
teristics that can be useful for patient selection. The use
of BVS in emergency bailout situations is currently not
supported. Also BVS implantation in patients on oral anti-
coagulants should be avoided because of the need of long-
term DAPT (≥3 years) due to the risk of very late ScT.
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Technical considerations for BVS implantation
We want to stress that an optimal BVS implantation tech-
nique will be of paramount importance for obtaining good
long-term clinical results [24]. Lesion preparation is es-
pecially important, as, before inflation, the initial scaffold
diameter is quite large (1.4 mm) which is related to the
specific scaffold-related folding characteristics of the Ab-
sorb BVS. Therefore, highly calcified or tortuous lesions
or lesions with a high degree of angulation can be quite
challenging for BVS implantation. However, with extensive
lesion pre-dilatation using increasing balloon sizes, even
calcified lesions can be successfully treated with BVS, al-
though special care has to be paid to a good implantation
technique. In summary, we advise the ‘P-S-P’ implantation
technique:
1. ‘Prepare the lesion’ aggressively using adequate predi-
latation (1:1 vessel-to-balloon ratio), We caution not to
implant BVS in lesions were predilatation balloons do
not fully expand.
2. ‘Size the vessel/scaffold correctly’. On-line QCA or
preferably invasive imaging (intravascular ultrasound
[IVUS] and optical coherence tomography [OCT]) is
advisable in general and indispensible in small vessels
(reference vessel diameter <3 mm or using a 2.5 mm
BVS scaffold). Evidently, undersizing has to be avoided
and never implant if the RVD is below 2.5 mm (measured
by invasive imaging).
3. ‘Post-dilate’ the scaffold with a properly sized non-com-
pliant balloon to avoid underexpansion (using a non-
compliant balloon with a diameter at least equal to and
preferably 0.5 mm larger than the RVD using high infla-
tion pressures [18–20 atm]).
Also, be aware of the expansion limits of the implanted
BVS as overexpansion of the scaffold can potentially lead
to scaffold fractures (maximal 0.5 mm larger than scaffold
diameter). The effect of a BVS specific implantation strat-
egy was deduced from a large registry covering four hospi-
tals and >1300 patients. After implementation of a specific
BVS implantation protocol, incidence of ScT was signifi-
cantly reduced (3.3% vs. 1.0% at 12 months for suboptimal
vs. optimal, respectively) [26]. In this retrospective analysis
failure to achieve a final minimal lumen diameter of 2.5 mm
for the small design (nominal 2.5 mm or 3.0 mm devices)
or 2.9 mm for the larger design (nominal 3.5 mm devices)
was an important factor in the occurrence of ScT.
To avoid BVS malapposition, correct scaffold sizing
based on a reliable assessment of vessel dimensions is
a second important issue. Invasive imaging modalities,
such as IVUS and OCT, can be of great value in provid-
ing accurate morphometry for estimating vessel diameter
and lesion length in circumstances where angiographic
assessment is ambiguous. OCT is particularly suited to
visualise the apposition of scaffold struts to the vessel wall
and can guide BVS optimisation [27]. Before implantation,
OCT is indicated to predetermine lesion characteristics,
such as vessel diameter, lesion length and the amount of
calcification, to estimate the optimal scaffold length and
to identify the optimal proximal and distal landing zones.
The importance of appropriate vessel sizing is becoming
increasingly clear, and, as already mentioned, BVS implan-
tation in vessels with a diameter of less than 2.25 mm on
quantitative coronary imaging (comparable with a diameter
of less than 2.5 mm on visual estimation) should be avoided
because of substantially worse clinical outcomes and an
elevated risk of ScT [4]. OCT after scaffold implantation
can be a helpful tool to guide postdilatation of the scaffold
with properly sized non-compliant balloons to optimise
strut apposition, taking into account the expansion limit of
0.5 mm for the Absorb BVS.
Antiplatelet therapy
DAPT has been the basis for minimising stent thrombosis
for many years. Current guidelines for antiplatelet therapy
advise DAPT for 6–12 months in stable angina patients re-
ceiving DES [28]. For ACS patients, based on the European
Society of Cardiology non-STEMI and STEMI guidelines
a minimum of 12 months of DAPT is advised, preferably
with prasugrel or ticagrelor [29, 30]. More recent publica-
tions suggest that for a low-risk population and when using
second generation DES, DAPT duration might be shortened
to 6 months [31, 32]. With the longer follow-up period of
larger registries and RCTs very late ScT has emerged as
a major problem. Timewise this might be related to the
resorption process of the BVS. Although in preclinical set-
tings this has never been noticed as a problem, the current
hypothesis is related to the expected degradation and disin-
tegration of devices without full embedment in the vessel
wall. Areas of malapposed, disintegrating struts might be-
come instable and trigger thrombosis. This might be an
additional risk factor to other already identified risk factors
for very late stent thrombosis.
The Dual Antiplatelet Therapy (DAPT) study demon-
strated that in patients who tolerated DAPT after DES im-
plantation for 12 months, without a bleeding complication,
DAPT up to 30 months, as compared with aspirin ther-
apy alone, significantly reduced the risks of stent thrombo-
sis and major adverse cardiovascular and cerebrovascular
events but was associated with an increased risk of bleed-
ing [33]. Within this very large (n = 11,648) randomised
study with 348 ischaemic events, multiple risk factors were
identified ([34]; Table 4) demonstrating the multifactorial
process of stent thrombosis, one of which was the use of
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Table 4 Predictors of myocar-
dial infarction or stent thrombo-
sis 12–30 months post-PCI in
the DAPT study
Predictors of MI or ST HR (95% CI) P value
MI at presentation 1.65 (1.31–2.07) <0.001
Prior PCI or prior myocardial infarction 1.79 (1.43–2.23) <0.001
History of CHF or LVEF <30% 1.88 (1.35–2.62) <0.001
Vein graft stent 1.75 (1.13–2.73) 0.01
Stent diameter <3 mm 1.61 (1.30–1.99) <0.001
Paclitaxel-eluting stent 1.57 (1.26–1.97) <0.001
Diabetes mellitus 1.38 (1.10–1.72) 0.01
Peripheral arterial disease 1.49 (1.05–2.13) 0.03
Hypertension 1.37 (1.03–1.82) 0.03
Renal insufficiency/failure 1.55 (1.03–2.32) 0.04
CHF congestive heart failure, LVEF left ventricular ejection fraction, MI myocardial infarction, PCI percu-
taneous coronary intervention, ST stent thrombosis
paclitaxel-eluting stents (with thick struts). Finally, a model
was developed balancing the increased bleeding risk of
prolonged DAPT duration with the reduction in ischaemic
events (DAPT score).
Recently, the PEGASUS-TIMI 54 trial [35] evaluated
long-term therapy with ticagrelor in addition to aspirin,
in patients with a history of spontaneous MI occurring
1–3 years prior to randomisation. The PEGASUS study
concluded that ticagrelor significantly reduced the risk of
MACE as compared with placebo. Recently, two meta-anal-
yses [36, 37] showed that DAPT beyond 1 year among sta-
bilised high-risk patients with prior MI decreased ischaemic
events at the cost of an increase in major bleeding. Udell
et al. showed that prolonged DAPT >1 year could reduce
the rate of stent thrombosis [36].
For the Absorb BVS a minimum of 6 months DAPT is
required per protocol (ABSORB-EXTEND, ABSORB II),
and the majority of patients in most studies received DAPT
for 12 months. Because of signals of a higher occurrence
of early as well as late, and even very late stent thrombosis
(beyond 1 year), currently and until further confirmation,
the best advice is to prescribe DAPT for a minimum of
3 years for BVS Absorb implanted patients in a tailored
approach including all known risk factors for very late stent
thrombosis and predictors of increased bleeding risk [22].
In all ACS patients and possibly also in patients with more
complex coronary lesions, there is a preference for the use
of the more potent P2Y12 inhibitors, such as ticagrelor or
prasugrel. As the prolongation of DAPT therapy from 1
to 3 years could prove to be harmful in specific patient
subgroups, certainly those with a higher bleeding tendency
and especially for patients already on oral anticoagulants, it
is recommended to avoid implantation of the Absorb BVS
in patients with a strict indication for oral anticoagulation.
Conclusions
The new 2017 recommendations downgrade and limit the
use of current BVS to experienced centres within dedicated
registries using the updated implantation protocol and ad-
vise the prolonged usage of DAPT in patients at high risk
of ischaemic events. Patient should be well informed on
the potential risks of the therapy and the only hypothetical
long-term benefit. This recommendation is based on recent
evidence from large randomised trials that implantation of
BVS is associated with increased risk of adverse events,
particularly increased risk of ScT and MI. In the near fu-
ture the COMPARE ABSORB trial will report additional
data regarding the appropriateness of BVS for PCI for spe-
cific lesion and patient subsets.
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